Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?
Where Today's News Shapes Tomorrow
